Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases. Vera's mission is to develop and commercialize transformative new therapies that improve patients' lives. Vera's lead program is atacicept, a fusion protein that is a dual inhibitor of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which is in development for IgA nephropathy (IgAN), also known as Berger's disease. Longer-term, the Company is building a pipeline of clinical-stage molecules with the potential to substantially improve lives. For more information please visit: www.veratx.com.